PrimeRFP SCOUT · Federal Contract Recompete Brief

HT942526FE010NOVEL bispecific BROAD spectrum nanobody — Eitr Biologics, Inc

Eitr Biologics, Inc holds $37.9M across 9 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 3 related awards under parent HT942523D0011. Recompete timing centers on the Dec 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

Army Med Res Acq Activity

Awarding office

Eitr Biologics, Inc

Recipient

Dec 31, 2027

PoP end

$927K

Obligated

$927K

Potential

541714

NAICS

AJ11

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Eitr Biologics, Inc — $90

Contract facts

Federal

Contract numberHT942526FE010

Also listed asHT942523D0011-HT942526FE010

AgencyArmy Med Res Acq Activity

Awarding officeArmy Med Res Acq Activity

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentEitr Biologics, Inc

CAGE99JH0

UEIHX49LZLY32G5

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAJ11

Parent IDIQ / IDVHT942523D0011

Place of performanceSAN DIEGO CA

Pricing typeFirm Fixed Price

Extent competedNot Competed

PoP startFeb 1, 2026

PoP end (current)Dec 31, 2027

Obligated$927K

Current value$927K

Potential value$927K

NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY is a federal award for Army Med Res Acq Activity held by Eitr Biologics, Inc. Estimated value $927K ($927K obligated). Current period of performance ends Dec 31, 2027. Place of performance: SAN DIEGO CA.

Recompete timing

Public

● Expiring in 497 days

Current PoP ends Dec 31, 2027 (497 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Jul 1, 2026.

Incumbent footprint

Public record

Eitr Biologics, Inc — $37.9M obligated across 9 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($37.9M) · all agencies

Department of Health and Human Services (HHS)$33.1M · 87%Department of Defense (DOD)$4.9M · 13%

Open full company profile →

Related awards

Same parent · incumbent

HT942524P0015

SORTING PERIPHERAL BLOOD MONONUCLEAR CELLS FROM LASSA FEVER VIRUS SURVIVORS TO DISCOVER AN…

$730K

Dec 10, 2026

HT942626FE033

NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY

$270K

Mar 31, 2027

75A50123C00060

THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTI…

$33.1M

Sep 30, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract HT942526FE010?

HT942526FE010 (NOVEL bispecific BROAD spectrum nanobody) is a Army Med Res Acq Activity award with a potential value of $927K, currently held by Eitr Biologics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HT942526FE010?

Army Med Res Acq Activity awarded HT942526FE010 to Eitr Biologics, Inc (potential $927K).

Who is the incumbent on HT942526FE010?

Eitr Biologics, Inc is the incumbent with $37.9M across 9 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2027.

When does Eitr Biologics, Inc’s HT942526FE010 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Jan 28, 2026